Section
The 2023 WHO EGASP study highlights a critical rise in ceftriaxone-resistant gonorrhea in Southeast Asia, with resistance reaching 20% in some regions. These findings underscore the urgent need for enhanced global surveillance and the accel
This phase 3 trial demonstrates that oral zoliflodacin is a viable, non-inferior alternative to ceftriaxone plus azithromycin for treating uncomplicated urogenital gonorrhoea, offering a critical solution to rising antibiotic resistance.
The GBD 2023 study highlights a 33.4% reduction in pediatric LRI mortality since 2010, yet 2.5 million annual deaths persist. While Streptococcus pneumoniae remains the primary pathogen, newly modeled aetiologies like non-tuberculous mycoba
A large-scale population-based study in Singapore reveals that acute dengue virus infection is associated with a nearly ten-fold increase in neurological events, including memory loss and movement disorders, particularly in older adults and
A multi-center randomized clinical trial published in JAMA Internal Medicine demonstrates that colchicine, despite its potent anti-inflammatory properties, fails to improve 6-minute walk test distances or inflammatory markers in patients su
The MULTI-CAP trial demonstrated that combining multiplex PCR and procalcitonin did not significantly increase the number of antibiotic-free days by Day 28 in ICU patients with pneumonia, although it did successfully reduce the cumulative d
Long-term data from the BArT study and prospective observational trials demonstrate that direct-acting antivirals (DAAs) can achieve 100% viral clearance and durable hematologic responses in HCV-associated indolent lymphomas, potentially re
A global genomic study of Helicobacter pylori reveals that mutations in 23S rRNA and gyrA predict antibiotic resistance with 100% sensitivity, signaling the end of empirical therapy in favor of genotype-based personalized treatment.
The OPTIC-2 phase 3b trial confirms that omadacycline is noninferior to moxifloxacin for treating community-acquired bacterial pneumonia (CABP). This once-daily aminomethylcycline offers a robust IV-to-oral monotherapy option with a favorab
A 36-week observational study demonstrates that subcutaneous lidocaine-HP-β-CD significantly improves physical and mental quality of life and reduces symptom burden in patients with post-COVID condition, offering a scalable, home-based ther
The RETRO-MENINGO study of 654 adults reveals that hemodynamic presentations of invasive meningococcal disease carry a five-fold higher mortality risk than neurological forms. Early parenteral antibiotic administration remains the most crit
A large-scale multinational study reveals that meropenem and piperacillin dosing during renal replacement therapy must be tailored to RRT intensity and urine output, with extended infusions significantly improving therapeutic target attainm
A large-scale study of over 300,000 ANZ ICU patients reveals that sepsis mortality plummeted from 28% to 11% between 2000 and 2020, followed by a concerning 0.9% annual increase through 2023, highlighting both clinical triumphs and emerging
The ANSWER-HF trial compared sacubitril-valsartan to enalapril in patients with Chagasic heart failure. Although the primary endpoint of LVEF improvement was not met at 6 months, significant reductions in NT-proBNP and a favorable win ratio
The FLUNITY-HD pooled analysis of over 466,000 older adults demonstrates that high-dose inactivated influenza vaccine (HD-IIV) significantly reduces hospitalizations for influenza, pneumonia, and cardiovascular causes, including a 21.3% red
Pregnant women show increased risk of long COVID-19 post-SARS-CoV-2 infection during Omicron predominance despite mild disease, yet incidence remains modest in a highly vaccinated cohort, highlighting vaccination’s protective role amidst em
Vaccination against SARS-CoV-2 during pregnancy significantly lowers risks of severe maternal COVID-19, hospitalization, critical care admission, and preterm birth across variant periods, underscoring its safety and efficacy for maternal an
A large-scale target trial emulation demonstrates that de-escalating anti-MRSA and anti-pseudomonal therapy on day 4 of sepsis treatment is safe, associated with fewer antibiotic days, and leads to shorter hospital stays compared to continu
A comprehensive meta-analysis of over 260,000 infants confirms that nirsevimab significantly reduces respiratory syncytial virus (RSV) and lower respiratory tract infection (LRTI) hospitalizations and emergency department visits, providing
An mHealth text messaging intervention significantly improves smoking cessation rates and reduces mortality among TB patients compared to usual care, supporting its implementation in TB programs.
